The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How you going to compare a company that's been around for longer than some of us have actually been around with a company that only just starting out ?!?!
Sure Apple didn't IPO and went vertical ever since then. What a load of 80110X
The whole objective in investing though is actually too get back more than you've invested.
While oxford no doubt is working hard on developing a product .
Reality is though if you've invested from ipo your down 80% .
You can spout all day long about a company's cutting edge technology etc etc .
The bottom line is your gambling on something that may never materialise and will continue to need fundung.
The money runs out in March.
If you'd invested at the same time as Oxford ipo'd
the over inflated Apple stock is up 35% since .
Well said @F458
I personally have no concerns with cash flow, as companies would love to get their hands on the exclusive patented licenses for medical grade cannabinoids.
The team have been working amazingly hard to establish top tier relationships with some of the best names in the industry. No way would Dr’s Paul and Tim put their names to this company, unless they were certain if it’s brilliance.
Everything Clarissa has said the company will do has been achieved and I have confidence that all future goals will be met.
Like you said, people have to do their own research but the doubters loss will be our gain 😁
Rabnesbit..
You are correct most early drug development companies do start with a high M/C at IPO because most buy into the concept of a product at early stage and the value of success does reflect the IPO value.
However where you have underestimated the value OCTP have placed themself in a market where a product that has been already used by many millions all over the world and has proven successful in its own right. OCTP are really just formulating an existing substance that as little side effects but already has proven ability to subdue pain. To achieve a secure medical certification which in return allows OCTP for its products to be either prescribed or over the counter is where OCTP has identified a huge gap in the market.
The trials are just a formality and any adjustment to their products to achieve the correct outcome will easily be achieved.
It's not that OCTP are trying to create a totally new product and have spent many years and £10's M 0n R & D but have been formulating a product that is safe to use. OCTP will start production in 2024. That's only around 3 years since IPO in 2021.
Given trials have commenced, I anticipate OCTP will be self funded by a JV. If it needs to raise it will be early 2024 on the back of positive results after phase 2 at which point the sp should be closer to or above IPO 5p.
The drop in the sp has not been by poor results or continued delays, But the markets have not digested what OCTP are doing and take the view that you have and therefore created a very undervalued company.
GL but DYOR
I followed this out of interest ever since IPO .
It's playing out exactly like 97-98% of drug development companies do on the market. Especially the nasdaq where most IPO at huge inflated M.C and make money solely on the flotation than they ever would as a company.
As an investment this is typical of this type of stonk to behave.
Lose 80% or more of the M.C after a couple of years than need to raise money to continue. usually a offering at a huge discount of the present MC ,that usually drops the SP well below the discounted price and of course the dilution with anything between 20-60% more shares .
Obviously the company will need too repeat that process again and again usually with just a slim chance of success of a product.
Not saying Oxford might or might not get a product onto the market . But 99% of the time investors lose heavily and the risk far out weighs the potential returns.
Think only positive here if BATC buys this but it's a slim chance.
..and all the large trades look like sells . Results soon so most likely folks taking risk off the table .
Most of them in the wrong direction by the looks of it
3.5 million trades already.
Might get news this week?
Https://twitter.com/OxCanTech/status/1691705693110186300
AI is essential for the future of drug discovery & development
“incorporating #ArtificialInteligence into drug discovery and development has the potential to revolutionise both patient experiences and outcomes”
My assumption is they will raise an additional tranche of development finance without a dilutive rights issue that would offer common shares at a discount.
From the details put out previously, they are funded until q1 2024.
That's not too far away. What is likely to happen when that point is reached ?
Would be nice to push up to year highs of 1.50 next week as we get nearer to results and news of phase 1 trials.
A quiet riser the best! Expected news & we surely bag. Keep it going…..
Wait up, I need more funds. Just opened my first small position here a few days ago, and after massive declines in all my other shares, good to see something performing.
12% rise! Looking good.
And now NT to buy anything
1.25 to buy now...creeping up
I would have thought the share price will be news and result driven hopefully moving into phase 2.
Feels primed for a big move - exciting month ahead. Can’t bag without being noticed it will come imho
Over 25% share price increase the past 2 weeks in OCTP, and yet it seems to have gone under radar in the market. Such will be the case if we 4 bag on news and only the chosen few shall reep the rewards 😁
You done any research into this or just looking at the charts ? The charts might look like a hold but the news to come in the near future and the potential of this company considering the people involved is enormous.....but you keep looking at lines and we tell you again in a few years if not months from now.....or just read up on rhe company should change your mind
At best a hold. The price chart looks terrible: flat to declining net money flow. Without an approved confirmed product for sale its a " dead duck " IMHO
That would be amazing Bamb if we saw 4p in the near future. Let’s face it, we’ve seen some terrible shares x20 recently with no material product whatsoever, yet OCTP have patent exclusivity and the contacts to make their research a unicorn.
One of OCTP’s goals was to make programme 1 available to the NHS and patients by 2027, but bringing in Dr Paul with his own CIPN practice is a move of excellence, as imo, it pretty much guarantees that as long as administered by a registered GP, medicine can reach pre-qualified patients much sooner.
Unofficial research by other industry professionals, already gives insight into what the outcome looks set to be, we just need that stamp of validation. Put the seat belt on, so they say!
Assuming we pass phase 1, this will be 3-4p in next month or so